Health stocks followed the broader market rollercoaster Friday -- a light news day for the sector despite the volatility.

The Nasdaq and Amex biotechnology indices ended down 3.2% and 3.56%, after rebounding from losses as great as 8% earlier in the day.

The Amex pharmaceutical index settled on a loss of 6.21, or 2.55%, at 237.48 by late afternoon -- every single component was in the red.

Wyeth

(WYE)

and

Teva

(TEVA) - Get Report

led losses, giving up 6.5% and 4.21%, respectively.

One of the few components of the Amex biotech index in positive territory,

Intermune

(ITMN)

shares gained 72 cents, or 5.3%, to $14.33 in late afternoon. No news was released.

Meanwhile,

Biogen Idec

(BIIB) - Get Report

said late Thursday that it is stopping development of baminercept in rheumatoid arthritis, after a failed midstage study. Shares were down $1.98, or 4.42%, at $42.78.

Medicis

(MRX)

said the FDA approved new labeling about the long-term effectiveness of wrinkle-filling drug Restylane based on new data. Medicis shares added $1.32, or 12.45%, to $11.92.

Next week

Genentech

(DNA)

will kick off

biotech earnings

, followed by

Gilead

(GILD) - Get Report

on Thursday. Genentech shares closed down $5.75, or 7.3%, to $73, and Gilead closed lost $2.57, or 6.4%, to $37.47.